What is it about?
We established that CD11a and PD-1 can be used as markers to identify endogenous tumor-reactive T cells in cancer patients.
Featured Image
Why is it important?
This study is important because we now have a method to monitor how patient's immune system respond to their cancers. This new method will help to identify new therapeutics, to monitor and predict patient responses to immunotherapy.
Perspectives
It is always a challenge to identify tumor-reactive T cell responses in cancer patients, this information is crucial for monitor and predict how cancer patients would respond to immunotherapy that is aimed to improve or restore anti-tumor immunity. Our study provides a new avenue for addressing this key question. We hope our results can be used as a platform for more discoveries in future in this field.
Dr. Haidong Dong
Mayo Clinic College of Medicine
Read the Original
This page is a summary of: Endogenous tumor-reactive CD8+T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth, OncoImmunology, June 2013, Taylor & Francis,
DOI: 10.4161/onci.23972.
You can read the full text:
Contributors
The following have contributed to this page
